3-ethoxy-1-adamantylamine | 1098072-03-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-ethoxy-1-adamantylamine
• 英文别名: 3-Ethoxyadamantan-1-amine
• CAS: 1098072-03-7
• 化学式: C₁₂H₂₁NO
• 分子量: 195.305
• InChiKey: AKPWQXXITUXNMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-ethoxy-1-adamantylamine 、 4-甲酰基肉桂酸甲酯 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 反应 4.0h， 生成 methyl 3-[4-[[(3-ethoxy-1-adamantyl)amino]methyl]phenyl]prop-2-enoate
  参考文献：
  名称：

  Discovery of adamantane based highly potent HDAC inhibitors

  摘要：

  Herein, we report the development of highly potent HDAC inhibitors for the treatment of cancer. A series of adamantane and nor-adamantane based HDAC inhibitors were designed, synthesized and screened for the inhibitory activity of HDAC. A number of compounds exhibited GI(50) of 10-100 nM in human HCT116, NCI-H460 and U251 cancer cells, in vitro. Compound 32 displays efficacy in human tumour animal xenograft model. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.03.002

文献信息

• ORGANIC COMPOUNDS
  申请人：Hassiepen Ulrich

  公开号：US20100256080A1

  公开（公告）日：2010-10-07

  The present invention relates to a compound The instant invention relates to a compound of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B), wherein R′ represents and R″ represents hydrogen, hydroxy, C 1 -C 7 alkoxy, C 1 -C 8 -alkanoyloxy, or R 5 R 4 N—CO—O—, where R 4 and R 5 independently are C 1 -C 7 alkyl or phenyl which is unsubstituted or substituted by a substitutent selected from C 1 -C 7 alkyl, C 1 -C 7 alkoxy, halogen and trifluoromethyl and where R 4 additionally is hydrogen; or R 4 and R 5 together represent C 3 -C 6 alkylene; in free form or in form of a pharmaceutically acceptable acid addition salt. Compounds of formulae (I A), (I B), (X A), (X B), (Y A) or (Y B) inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

  本发明涉及一种化合物。本发明涉及一种具有式(I A)、(I B)、(X A)、(X B)、(Y A)或(Y B)的化合物，其中R′代表，R″代表氢、羟基、C1-C7烷氧基、C1-C8-烷酰氧基，或R5R4N—CO—O—，其中R4和R5独立地为C1-C7烷基或苯基，未取代或被C1-C7烷基、C1-C7烷氧基、卤素和三氟甲基等取代基取代，且R4另外为氢；或者R4和R5共同表示C3-C6烷基链；以自由形式或药学上可接受的酸盐形式存在。式(I A)、(I B)、(X A)、(X B)、(Y A)或(Y B)的化合物抑制DPP-IV（二肽基肽酶-IV）活性。因此，它们适用于作为药物用于抑制DPP-IV和治疗由DPP-IV介导的疾病，如非胰岛素依赖型糖尿病、关节炎、肥胖症、骨质疏松症以及其他葡萄糖耐量受损疾病。
• [EN] N-SUBSTITUTED 2-CYANOPYRROLIDINES<br/>[FR] 2-CYANOPYRROLIDINES N-SUBSTITUES
  申请人：NOVARTIS AG

  公开号：WO2000034241A1

  公开（公告）日：2000-06-15

  The present invention relates to a compound of formula (I), wherein R is substituted adamantyl; and n is 0 to 3; in free form or in acid addition salt form. Compounds of formula (I) inhibit DPP-IV (dipeptidyl-peptidase-IV) activity. They are therefore indicated for use as pharmaceuticals in inhibiting DPP-IV and in the treatment of conditions mediated by DPP-IV, such as non-insulin-dependent diabetes mellitus, arthritis, obesity, osteoporosis and further conditions of impaired glucose tolerance.

  本发明涉及一种式为(I)的化合物，其中R是取代的金刚烷基；n为0至3；以自由形式或酸加成盐形式存在。式(I)的化合物能够抑制DPP-IV（二肽基肽酶-IV）的活性。因此，它们适用于作为药物用于抑制DPP-IV和治疗由DPP-IV介导的疾病，如非胰岛素依赖性糖尿病、关节炎、肥胖症、骨质疏松症和其他葡萄糖耐量受损的疾病。
• Compound for resist and radiation-sensitive composition
  申请人：MITSUBISHI GAS CHEMICAL COMPANY, INC.

  公开号：EP2662727A2

  公开（公告）日：2013-11-13

  A radiation-sensitive composition containing 1 to 80% by weight of a solid component and 20 to 99% by weight of a solvent. The solid component contains a compound B which has (a) a structure derived from a polyphenol compound A by introducing an acid-dissociating group to at least one phenolic hydroxyl group of the polyphenol compound A which is synthesized by a condensation between a compound selected from the group consisting of compounds such as for instance diformylbenzene, diacetylbenzene and diformyltoluene; or a di- to tetrafunctional aromatic ketone or aromatic aldehyde each having 12 to 36 carbon atoms with a compound having 1 to 3 phenolic hydroxyl groups and 6 to 15 carbon atoms, and (b) a molecular weight of 400 to 2000. The composition containing the compound B is useful as an acid-amplified, non-polymeric resist material, because it is highly sensitive to radiation such as KrF excimer lasers, extreme ultraviolet rays, electron beams, and X-rays, and provides resist patterns with a high resolution, high heat resistance, and high etching resistance.

  一种辐射敏感组合物，含有 1%至 80%（按重量计）的固体成分和 20%至 99%（按重量计）的溶剂。固体成分含有一种化合物 B，该化合物 B 具有 (a) 由多酚类化合物 A 衍生出的结构，该结构是通过在多酚类化合物 A 的至少一个酚羟基上引入酸解离基团而形成的，该多酚类化合物 A 是由选自以下组成的化合物组的化合物缩合合成的：例如二甲酰基苯、二乙酰基苯和二甲酰基甲苯；(b) 分子量为 400 至 2000。含有化合物 B 的组合物可用作酸放大的非聚合抗蚀剂材料，因为它对诸如 KrF 准分子激光、极紫外线、电子束和 X 射线等辐射高度敏感，并能提供具有高分辨率、高耐热性和高抗蚀性的抗蚀图案。
• N-SUBSTITUTED 2-CYANOPYRROLIDINES
  申请人：Novartis AG

  公开号：EP1137635B1

  公开（公告）日：2005-10-19
• ADAMANTYL O-GLUCURONIDE DERIVATIVES AS INHIBITORS OF DIPEPTIDYL PEPTIDASE IV FOR THE TREATMENT OF DIABETES
  申请人：Novartis AG

  公开号：EP2247602A2

  公开（公告）日：2010-11-10